Search research articles
Contact Us
Filters
Showing results (141-150 of 152) with videos related to
Page
of 16
Sort By:
Anticancer Research
|
August 15, 2001
Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk
A Gsur, G Haidinger, P Hollaus, et al.
Annals of Hematology
|
April 22, 1999
G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability
G Fischmeister, M Kurz, O A Haas, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1981
Effectiveness of postoperative adjuvant therapy with cytotoxic chemotherapy (cytosine arabinoside, mitomycin C, 5-fluorouracil) or immunotherapy (neuraminidase-modified allogeneic cells) in the prevention of recurrence of Duke's B and C colon cancer
H Rainer, E Kovats, H G Lehmann, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
April 8, 2006
Anticancer effects of zoledronic acid against human osteosarcoma cells
B Kubista, K Trieb, F Sevelda, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
Acta Medica Austriaca. Supplement
|
January 1, 1979
[Prognostic factors in the drug therapy of metastasizing breast cancer]
R Mörz, M Schemper, P Bettelheim, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
British Journal of Cancer
|
August 14, 2003
Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk
A Gsur, T Zidek, K Schnattinger, et al.
Current Cancer Drug Targets
|
June 11, 2009
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)
P Heffeter, A Popovic-Bijelic, P Saiko, et al.
Bulletin Du Cancer
|
August 10, 2001
[Recommendations on cancer screening in the European Union]
M Micksche, E Lynge, V Diehl, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 152) with videos related to
Sort By:
Page
of 16
Anticancer Research
|
August 15, 2001
Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk
A Gsur, G Haidinger, P Hollaus, et al.
Annals of Hematology
|
April 22, 1999
G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability
G Fischmeister, M Kurz, O A Haas, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1981
Effectiveness of postoperative adjuvant therapy with cytotoxic chemotherapy (cytosine arabinoside, mitomycin C, 5-fluorouracil) or immunotherapy (neuraminidase-modified allogeneic cells) in the prevention of recurrence of Duke's B and C colon cancer
H Rainer, E Kovats, H G Lehmann, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
April 8, 2006
Anticancer effects of zoledronic acid against human osteosarcoma cells
B Kubista, K Trieb, F Sevelda, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
Acta Medica Austriaca. Supplement
|
January 1, 1979
[Prognostic factors in the drug therapy of metastasizing breast cancer]
R Mörz, M Schemper, P Bettelheim, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
British Journal of Cancer
|
August 14, 2003
Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk
A Gsur, T Zidek, K Schnattinger, et al.
Current Cancer Drug Targets
|
June 11, 2009
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)
P Heffeter, A Popovic-Bijelic, P Saiko, et al.
Bulletin Du Cancer
|
August 10, 2001
[Recommendations on cancer screening in the European Union]
M Micksche, E Lynge, V Diehl, et al.
Page
of 16